- Indication: Rheumatoid Arthritis
- Enrollment Status: Pre-Enrollment
- Protocol: IMVT-1402-2601
- Drug: IMVT-1402
- Sponsor: Immunovant
- Description: A Phase 2b, Multicenter, Double-blind, Placebo-controlled Randomized Withdrawal Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants with Active, Difficult-to-treat, ACPA-Positive Rheumatoid Arthritis
- Indication: Rheumatoid Arthritis
- Enrollment Status: Enrollment Closed
- Protocol: PRIMA-102 “Aqtual”
- Drug: N/A: Collection for Assessment of DMARD Initiation
- Sponsor: Aqtual
- Description: Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants with Rheumatoid Arthritis with inadequate response or intolerance to a DMARD Starting a New bDMARD or tsDMARD Treatment +/- csDMARD
- Indication: Rheumatoid Arthritis
- Enrollment Status: Enrollment Closed
- Protocol: GS-US-417-0304
- Drug: Filgotinib
- Sponsor: Gilead
- Description: A Multicenter, Open-Label, Long-Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis
